688331 荣昌生物
已收盘 04-10 15:00:00
资讯
新帖
简况
荣昌生物新药维迪西妥单抗获批用于治疗HER2阳性尿路上皮癌
美股速递 · 04-10 22:36
荣昌生物新药维迪西妥单抗获批用于治疗HER2阳性尿路上皮癌
荣昌生物：公司2025年第四季度利润增长主要系公司在第四季度确认了与Vor Biopharma Inc.就RC18达成的授权许可首付款收入
证券日报 · 04-10 19:28
荣昌生物：公司2025年第四季度利润增长主要系公司在第四季度确认了与Vor Biopharma Inc.就RC18达成的授权许可首付款收入
荣昌生物：维迪西妥单抗新适应症获批准
每日经济新闻 · 04-10 16:56
荣昌生物：维迪西妥单抗新适应症获批准
荣昌生物（688331）披露2025年度持续督导现场检查报告，4月7日股价下跌4.99%
证券之星 · 04-07
荣昌生物（688331）披露2025年度持续督导现场检查报告，4月7日股价下跌4.99%
每周股票复盘：荣昌生物（688331）双抗ADC药物获临床试验批准
证券之星 · 04-05
每周股票复盘：荣昌生物（688331）双抗ADC药物获临床试验批准
中金：维持荣昌生物(09995)跑赢行业评级 上调目标价至133.7港元
智通财经 · 04-03
中金：维持荣昌生物(09995)跑赢行业评级 上调目标价至133.7港元
口服减重新突破，每日一粒告别针头！礼来口服GLP1药在美获批
新浪基金 · 04-03
口服减重新突破，每日一粒告别针头！礼来口服GLP1药在美获批
荣昌生物（688331）披露双抗ADC药物RC288获临床试验批准通知书，4月2日股价上涨4.12%
证券之星 · 04-02
荣昌生物（688331）披露双抗ADC药物RC288获临床试验批准通知书，4月2日股价上涨4.12%
盈利转正、BD落地，荣昌生物全球化布局走到哪一步？
21世纪经济报道 · 04-02
盈利转正、BD落地，荣昌生物全球化布局走到哪一步？
荣昌生物双特异性抗体偶联药物RC288注射液获中国药监局临床试验批准
美股速递 · 04-01
荣昌生物双特异性抗体偶联药物RC288注射液获中国药监局临床试验批准
荣昌生物(688331.SH)：双抗ADC药物注射用RC288获得药物临床试验批准通知书
智通财经 · 04-01
荣昌生物(688331.SH)：双抗ADC药物注射用RC288获得药物临床试验批准通知书
【券商聚焦】交银国际维持荣昌生物(09995)买入评级 指盈亏平衡可期
金吾财讯 · 03-31
【券商聚焦】交银国际维持荣昌生物(09995)买入评级 指盈亏平衡可期
3月30日荣昌生物涨5.52%，万家行业优选LOF基金重仓该股
证券之星 · 03-30
3月30日荣昌生物涨5.52%，万家行业优选LOF基金重仓该股
部分创新药概念股逆市上扬 荣昌生物(09995)涨4.99%
金吾财讯 · 03-30
部分创新药概念股逆市上扬 荣昌生物(09995)涨4.99%
港股异动 | 荣昌生物(09995)涨超8% 全年扭亏为盈赚超7亿元 收入同比大增近九成
智通财经 · 03-30
港股异动 | 荣昌生物(09995)涨超8% 全年扭亏为盈赚超7亿元 收入同比大增近九成
每周股票复盘：荣昌生物（688331）2025年净利润7.1亿元同比增148.33%
证券之星 · 03-29
每周股票复盘：荣昌生物（688331）2025年净利润7.1亿元同比增148.33%
荣昌生物(09995)发布年度业绩，股东应占收益7.1亿元 同比扭亏为盈
智通财经 · 03-27
荣昌生物(09995)发布年度业绩，股东应占收益7.1亿元 同比扭亏为盈
荣昌生物：董事会审议通过《关于公司<2025年度总经理工作报告>的议案》等多项议案
证券日报网 · 03-27
荣昌生物：董事会审议通过《关于公司<2025年度总经理工作报告>的议案》等多项议案
荣昌生物（688331）披露维迪西妥单抗新增适应症获批公告，3月23日股价下跌4.64%
证券之星 · 03-23
荣昌生物（688331）披露维迪西妥单抗新增适应症获批公告，3月23日股价下跌4.64%
荣昌生物(688331.SH)：维迪西妥单抗用于治疗HER2低表达且存在肝转移的乳腺癌适应症上市申请获得批准
智通财经 · 03-23
荣昌生物(688331.SH)：维迪西妥单抗用于治疗HER2低表达且存在肝转移的乳腺癌适应症上市申请获得批准
加载更多
公司概况
公司名称：
荣昌生物制药(烟台)股份有限公司
所属行业：
医药制造业
上市日期：
2022-03-31
主营业务：
荣昌生物制药(烟台)股份有限公司的主营业务是研发、生产和销售医药产品、诊断试剂产品。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC148、RC278、RC288。
发行价格：
48.00
{"stockData":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":135.48,"timestamp":1775804400000,"preClose":137.79,"halted":0,"volume":9036233,"delay":0,"changeRate":-0.0168,"floatShares":163000000,"shares":564000000,"eps":5.1157,"marketStatus":"已收盘","change":-2.31,"latestTime":"04-10 15:00:00","open":137,"high":138.47,"low":132.15,"amount":1228000000,"amplitude":0.0459,"askPrice":135.48,"askSize":2,"bidPrice":135.45,"bidSize":3,"shortable":0,"etf":0,"ttmEps":5.1157,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776043800000},"marketStatusCode":5,"adr":0,"adjPreClose":137.79,"symbolType":"stock_kcb","openAndCloseTimeList":[[1775784600000,1775791800000],[1775797200000,1775804400000]],"highLimit":151.57,"lowLimit":124.01,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":564477483,"isCdr":false,"pbRate":21.19,"roa":"--","peRate":26.483179,"roe":"24.87%","epsLYR":1.29,"committee":-0.097744,"marketValue":76475000000,"turnoverRate":0.0554,"status":1,"afterMarket":{"amount":0,"volume":0,"close":135.48,"buyVolume":0,"sellVolume":300,"time":1775806437558,"indexStatus":"已收盘 04-10 15:30:00","preClose":137.79},"hkstockBrief":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":106,"timestamp":1775808560009,"preClose":107.7,"halted":0,"volume":4506096,"delay":0,"premium":"-31.74"},"floatMarketCap":22096000000},"requestUrl":"/m/hq/s/688331","defaultTab":"news","newsList":[{"id":"1191656067","title":"荣昌生物新药维迪西妥单抗获批用于治疗HER2阳性尿路上皮癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1191656067","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191656067?lang=zh_cn&edition=full","pubTime":"2026-04-10 22:36","pubTimestamp":1775831783,"startTime":"0","endTime":"0","summary":"荣昌生物制药股份有限公司宣布，其创新药物维迪西妥单抗（Disitamab Vedotin）的新药上市申请已正式获得批准，适应症为HER2表达阳性的尿路上皮癌。这一重要进展为相关患者群体提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2148510915.USD","LU1064130708.USD","BK0239","LU2488822045.USD","688331","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626192923","title":"荣昌生物：公司2025年第四季度利润增长主要系公司在第四季度确认了与Vor Biopharma Inc.就RC18达成的授权许可首付款收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2626192923","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626192923?lang=zh_cn&edition=full","pubTime":"2026-04-10 19:28","pubTimestamp":1775820480,"startTime":"0","endTime":"0","summary":"证券日报网讯4月10日，荣昌生物在互动平台回答投资者提问时表示，公司2025年第四季度利润增长主要系公司在第四季度确认了与VorBiopharmaInc.就RC18达成的授权许可首付款收入，该笔收入在第四季度完成相关合同义务履行并确认。同时，核心产品泰它西普、维迪西妥单抗的销售收入亦保持良好增长态势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604103701423440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","688331","BK1161","LU2328871848.SGD","LU1064130708.USD","LU2148510915.USD","VOR","LU2488822045.USD","LU1064131003.USD","09995","BK1583","BK4139","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626193856","title":"荣昌生物：维迪西妥单抗新适应症获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2626193856","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626193856?lang=zh_cn&edition=full","pubTime":"2026-04-10 16:56","pubTimestamp":1775811411,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月10日，荣昌生物(688331.SH)公告称，公司近日收到国家药监局核准签发的《药品注册证书》，维迪西妥单抗联合特瑞普利单抗用于治疗HER2表达的局部晚期或转移性尿路上皮癌的新适应症上市申请获得批准。这是维迪西妥单抗在国内获批的第五项适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604103701182236.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604103701182236.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","688331","BK1161","LU2328871848.SGD","LU1064130708.USD","LU2148510915.USD","LU2488822045.USD","LU1064131003.USD","09995","BK1583","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625936395","title":"荣昌生物（688331）披露2025年度持续督导现场检查报告，4月7日股价下跌4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625936395","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625936395?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:07","pubTimestamp":1775552830,"startTime":"0","endTime":"0","summary":"截至2026年4月7日收盘，荣昌生物报收于141.66元，较前一交易日下跌4.99%，最新总市值为799.64亿元。近日，荣昌生物披露《华泰联合证券有限责任公司关于荣昌生物制药（烟台）股份有限公司2025年度持续督导现场检查报告》。公告显示，华泰联合证券作为保荐机构，于2026年3月31日对荣昌生物2025年度的公司治理、内部控制、信息披露、独立性、募集资金使用、关联交易、对外担保、重大对外投资及经营状况等情况进行了现场检查。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700023601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","BK1161","BK0239","LU1969619763.USD","BK1583","LU2328871848.SGD","LU1064131003.USD","LU2148510915.USD","BK1574","LU1064130708.USD","LU2488822045.USD","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625957616","title":"每周股票复盘：荣昌生物（688331）双抗ADC药物获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2625957616","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625957616?lang=zh_cn&edition=full","pubTime":"2026-04-05 02:08","pubTimestamp":1775326093,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，荣昌生物报收于149.1元，较上周的123.58元上涨20.65%。本周，荣昌生物4月2日盘中最高价报150.54元，股价触及近一年最高点。本次获批不影响公司近期业绩，后续需完成临床试验并经审批方可上市。华泰联合证券作为保荐机构，于2026年3月31日完成对荣昌生物2025年度持续督导现场检查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","09995","BK0239","LU1969619763.USD","LU1064130708.USD","BK1161","LU2328871848.SGD","LU2488822045.USD","BK1574","BK1583","688331","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624403631","title":"中金：维持荣昌生物(09995)跑赢行业评级 上调目标价至133.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624403631","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624403631?lang=zh_cn&edition=full","pubTime":"2026-04-03 10:38","pubTimestamp":1775183931,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，考虑荣昌生物授权合作收入确认节奏，上调2026年净利润由0.34亿元至42.35亿元，并引入2027年净利润预测7.48亿元。考虑RC148国际化研发提速及业绩改善，基于DCF估值，该行维持跑赢行业评级，上调目标价26.8%至133.7港元，较当前股价有21.1%的上行空间。中金主要观点如下：2025年业绩超过该行预期公司公布2025年业绩：收入32.42亿元，同比增长89.55%;归母净利润7.10亿元，实现扭亏为盈。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424994.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688331","09995","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624311466","title":"口服减重新突破，每日一粒告别针头！礼来口服GLP1药在美获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2624311466","media":"新浪基金","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624311466?lang=zh_cn&edition=full","pubTime":"2026-04-03 10:31","pubTimestamp":1775183460,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局于本周三批准了礼来公司的口服GLP-1药物Foundayo上市，标志着礼来迎来一个重要里程碑，并为进一步测试此类新型减肥药物的市场潜力提供了机会。消息公布后，礼来股价当日盘中上涨超过5%。该每日一次口服药物预计下周一起通过礼来直销平台LillyDirect开始发货，并将很快在各大药房及远程医疗平台上架销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/2026-04-03/doc-inhtetzf3810120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2237443895.HKD","BK4007","LU2552382132.HKD","LU1551013342.USD","SG9999014914.USD","IE00B4JS1V06.HKD","LU1551013425.SGD","SGXZ31699556.SGD","SG9999015945.SGD","LU2750360997.AUD","IE00B2B36J28.USD","LU2552382058.USD","LU1629891620.HKD","LU2028103732.USD","LU1232071149.USD","LU0689472784.USD","LU1988902786.USD","LU0079474960.USD","LU0640476718.USD","LU2087625088.SGD","LU2237443382.USD","IE00BN29S564.USD","LU2471134796.USD","IE00BJJMRY28.SGD","SG9999014898.SGD","IE00B4R5TH58.HKD","LU2089284900.SGD","LU0683600562.USD","LU0198837287.USD","LU2491049909.HKD","LU0354030438.USD","LU0471298694.HKD","LU2237438978.USD","LU0708995401.HKD","LU2462157665.USD","SG9999018865.SGD","LU0225283273.USD","LU2271345857.HKD","LU0456855351.SGD","LU0466842654.USD","LU0203201768.USD","LU2471134523.USD","LU0109394709.USD","LU1323610961.USD","LU0256863902.USD","LU2896262040.SGD","LLYX","LU1057294990.SGD","LU1868837300.USD","LU2168564222.USD","688331","LU0882574139.USD","LU0823416689.USD","LU2417539215.USD","LU2602419157.SGD","LU0786609619.USD","IE00BWXC8680.SGD","LU0787776722.HKD","LU2236285917.USD","LU2111349929.HKD","LU2324357040.USD","IE00BJJMRX11.SGD","LU1069344957.HKD","LU0354030511.USD","LU1548497426.USD","IE00BJJMRZ35.SGD","SGXZ57979304.SGD","BK4588","LU1983299246.USD","LU2746668974.SGD","LU1989771016.USD","SGXZ99366536.SGD","LU0114720955.EUR","LU0106261372.USD","LU0882574055.USD","IE00BKDWB100.SGD","LU2750360641.GBP","LU1280957306.USD","IE0001KFT4U8.USD","LU0058720904.USD","LU0943347566.SGD","LU1093756168.USD","LU2213496289.HKD","IE00B775H168.HKD","LU2471134879.HKD","SG9999001176.SGD","LLY","IE00BFSS8Q28.SGD","LU1804176565.USD","LU1127390331.HKD","LU2237443978.SGD","LU0823434583.USD","LU2237443465.HKD","LU1868837136.USD","IE00B1XK9C88.USD","LU2491050154.USD","BK4599","SG9999015952.SGD","LU2491050071.SGD","LU1720051108.HKD","LU0210536198.USD","BK4533","SHWGY","LU0889565916.HKD","LU0234572021.USD","LU1712237335.SGD","LLII","LU0471298777.SGD","LU2237443622.USD","LU0256863811.USD","IE0004445015.USD","LU0823434740.USD","LU2168564149.EUR","LU2456880835.USD","BK4581","09995","LU0203202063.USD","LU1267930730.SGD","LU2746668461.USD","BK4585","LU2168564065.EUR","LU1868836591.USD","IE00BK4W5L77.USD","LU0316494557.USD","SG9999013999.USD","IE00B1BXHZ80.USD","LU2112291526.USD","LU0096364046.USD","IE00BFTCPJ56.SGD","LU1623119135.USD","LU2168563687.JPY","LU0385154629.USD","IE00B7KXQ091.USD","LU2471134952.CNY","LU2089984988.USD","IE00BFSS7M15.SGD","01066","GB00BDT5M118.USD","LU0238689110.USD","LU1061106388.HKD","LU2063271972.USD","SG9999015986.USD","LU0061475181.USD","IE0005OL40V9.USD","LU0672654240.SGD","LLYZ","LU1868836914.USD","LU2361044865.SGD","LU0820562030.AUD","SG9999015978.USD","LU2023250330.USD","LU1035775433.USD","LU2211815571.USD","LU2468319806.SGD","SG9999018857.SGD","LU1917777945.USD","IE0002141913.USD","LU1145028129.USD","LU0006306889.USD","LU2756315664.SGD","IE0009355771.USD","LU0109391861.USD","LU0320765059.SGD","LU0122379950.USD","LU1064131342.USD","SG9999014880.SGD","LU0417517546.SGD","LU2360106947.USD","LU1974910355.USD","LU1366192091.USD","LU0158827948.USD","LU2023251221.USD","LU1023059063.AUD","LU0353189763.USD","LU2552382215.SGD","LU1720051017.SGD","ELIS","IE00BK4W5M84.HKD","LU2089283258.USD","IE00BKPKM429.USD","LU0353189680.USD","LU2023250504.SGD","SG9999017495.SGD","LU2264538146.SGD","IE00BJT1NW94.SGD","LU2361045086.USD","LU2756315318.SGD","SG9999001176.USD","LU0158827781.USD","LU2108987350.USD","LU2361044949.HKD","LU2168564495.EUR","LU0323591593.USD","BK4534","BK4516","LU1868836757.USD","ELIL","IE0004445239.USD","LU2237443549.SGD","LU0097036916.USD","LU0820561818.USD","LU1093756325.SGD","LU1291159041.SGD","LU2106854487.HKD","IE00BJLML261.HKD","LU0320765992.SGD","LU0820561909.HKD","SG9999014906.USD","LU0094547139.USD","LU1814569148.SGD","LU2357305700.SGD","LU0964807845.USD","LU0432979614.USD","SGXZ51526630.SGD","LU0289739699.SGD","LU2265009873.SGD","LU2461242641.AUD","LU0266013472.USD","SGXZ81514606.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624024295","title":"荣昌生物（688331）披露双抗ADC药物RC288获临床试验批准通知书，4月2日股价上涨4.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624024295","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624024295?lang=zh_cn&edition=full","pubTime":"2026-04-02 22:02","pubTimestamp":1775138548,"startTime":"0","endTime":"0","summary":"截至2026年4月2日收盘，荣昌生物报收于149.93元，较前一交易日上涨4.12%，最新总市值为846.32亿元。荣昌生物制药（烟台）股份有限公司近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司自主研发的双抗ADC药物注射用RC288单药治疗局部晚期不可切除或转移性恶性实体肿瘤的I/Ⅱa期临床试验获得批准。RC288是一款同时靶向PSMA和B7H3的双特异性ADC，采用新一代偶联及毒素技术开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200041675.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","LU2328871848.SGD","LU1969619763.USD","BK1574","BK0239","LU2488822045.USD","BK1583","688331","LU2148510915.USD","LU1064130708.USD","BK1161","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624780521","title":"盈利转正、BD落地，荣昌生物全球化布局走到哪一步？","url":"https://stock-news.laohu8.com/highlight/detail?id=2624780521","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624780521?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:10","pubTimestamp":1775099411,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者韩利明实习生蒋雨桐受益于核心产品商业化放量，叠加BD（商务拓展）授权收入贡献，荣昌生物（688331.SH；09995.HK）交出近三年来最优业绩答卷。2025年年报显示，期内公司实现营业收入32.51亿元，同比上涨89.36%；归母净利润扭亏为盈，达7.1亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604023693148433.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604023693148433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2148510915.USD","LU2488822045.USD","BK1583","BK1161","LU2328871848.SGD","LU1969619763.USD","LU1064131003.USD","09995","LU1064130708.USD","688331","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163264510","title":"荣昌生物双特异性抗体偶联药物RC288注射液获中国药监局临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1163264510","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163264510?lang=zh_cn&edition=full","pubTime":"2026-04-01 22:30","pubTimestamp":1775053845,"startTime":"0","endTime":"0","summary":"荣昌生物近日宣布，其研发的双特异性抗体偶联药物（Bispecific ADC）RC288注射液已获得中国国家药品监督管理局（NMPA）的临床试验批准。这一进展标志着公司在创新药物研发领域取得重要突破。\nRC288作为一款双特异性抗体药物偶联物，结合了抗体靶向性和细胞毒性药物的杀伤力，有望为相关疾病治疗提供新的解决方案。此次获批进入临床阶段，将为后续研究奠定基础。\n公司表示，将积极推进RC288的临床试验工作，探索其在适应症中的安全性和有效性。该进展也体现了中国在生物医药领域的创新能力和监管支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2148510915.USD","BK0239","LU1064130708.USD","LU2488822045.USD","LU1064131003.USD","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624596896","title":"荣昌生物(688331.SH)：双抗ADC药物注射用RC288获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2624596896","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624596896?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:45","pubTimestamp":1775033156,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物 发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司自主研发的双抗ADC药物RC288单药治疗局部晚期不可切除或转移性恶性实体肿瘤的I/Ⅱa期临床试验获得批准。RC288是一款同时靶向PSMA和B7H3的双特异性ADC，是荣昌生物采用新一代偶联及毒素技术开发的创新药物分子。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","ADC","BK0239","BK1574","LU1064130708.USD","09995","LU2328871848.SGD","BK1583","BK4080","LU2148510915.USD","LU1064131003.USD","BK4231","LU2488822045.USD","LU1969619763.USD","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623371411","title":"【券商聚焦】交银国际维持荣昌生物(09995)买入评级 指盈亏平衡可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2623371411","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623371411?lang=zh_cn&edition=full","pubTime":"2026-03-31 11:04","pubTimestamp":1774926260,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，2025年，荣昌生物 产品销售收入同比+35.8%至23.07亿元，其中：1）泰它西普销售+42%至13.9 亿元，SLE仍为贡献最大的适应症，肾科和神免快速增长中、未来占比将提升；2）维迪西妥销售+22.5%至 8.8 亿元，UC 适应症贡献约70%，近期获批的乳腺癌伴肝转移有望在2026年带来较大销售贡献。此外，多项BD授权交易推动许可收入达8.95亿元。维持136港元目标价，维持买入评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977831","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688331","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623972353","title":"3月30日荣昌生物涨5.52%，万家行业优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623972353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623972353?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:26","pubTimestamp":1774859184,"startTime":"0","endTime":"0","summary":"证券之星消息，3月30日荣昌生物涨5.52%创60日新高，收盘报130.4元，换手率8.28%，成交量13.51万手，成交额17.7亿元。重仓荣昌生物的前十大公募基金请见下表：该股最近90天内共有6家机构给出评级，买入评级5家，增持评级1家；过去90天内机构目标均价为147.85。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共50家，其中持有数量最多的公募基金为万家基金的万家行业优选LOF。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000021503.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK1583","LU1064131003.USD","688331","160916","LU2328871848.SGD","09995","LU1064130708.USD","LU2488822045.USD","BK0239","BK1161","LU1969619763.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623678703","title":"部分创新药概念股逆市上扬 荣昌生物(09995)涨4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623678703","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623678703?lang=zh_cn&edition=full","pubTime":"2026-03-30 10:23","pubTimestamp":1774837415,"startTime":"0","endTime":"0","summary":"金吾财讯 | 部分创新药概念股逆市上扬，荣昌生物 涨4.99%，康方生物涨4.75%，诺诚健华涨3.66%，先声药业涨2.73%，远大医药涨2.65%，和黄医药涨1.37%。据人民日报从国家药监局获悉，今年截至目前，我国创新药对外授权交易总额超过600亿美元，接近2025年全年的一半。今年截至3月27日，我国共批准上市10款创新药，其中8款是中国原创新药。2025年，我国批准创新药76个，创历史新高；创新药对外授权交易总金额突破1300亿美元，同样创历史新高。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977637","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2476274308.USD","LU0348783233.USD","BK0239","159992","LU0348784397.USD","LU0540923850.HKD","09969","LU2488822045.USD","LU0417516738.SGD","688331","LU0348767384.USD","LU0561508036.HKD","IE00B5MMRT66.SGD","BK1161","BK1574","LU0348827113.USD","09995","IE00B543WZ88.USD","06978","LU2476274720.SGD","LU1064131003.USD","LU0348766576.USD","LU2778985437.USD","LU0348735423.USD","BK1583","LU0417516571.SGD","LU1794554557.SGD","LU2148510915.USD","09926","00013","LU0348825331.USD","LU0417516902.SGD","LU1969619763.USD","LU0634319403.HKD","LU1064130708.USD","LU1720050803.USD","LU2399975544.HKD","LU1961090484.USD","IE00BPRC5H50.USD","00512","BK1587","LU2328871848.SGD","BK1588","02096","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623625553","title":"港股异动 | 荣昌生物(09995)涨超8% 全年扭亏为盈赚超7亿元 收入同比大增近九成","url":"https://stock-news.laohu8.com/highlight/detail?id=2623625553","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623625553?lang=zh_cn&edition=full","pubTime":"2026-03-30 09:53","pubTimestamp":1774835613,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物涨超8%，截至发稿，涨8.13%，报101.8港元，成交额2.84亿港元。消息面上，荣昌生物发布2025年度业绩，该集团取得收益人民币32.42亿元，同比增加89.55%；母公司拥有人应占收益7.1亿元，去年同期则取得亏损14.68亿元。该行指，25年BD收入约9亿元，主要来自泰它西普授权首付款及认股权证；26年RC28、RC148授权首付款将陆续确认，且RC148有望达成多项临床里程碑，进一步支撑收入跨越式增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09995","BK1161","BK0239","LU1969619763.USD","BK1583","LU2328871848.SGD","VXUS","LU1064131003.USD","LU2148510915.USD","BK1574","LU1064130708.USD","BK4585","BK4588","LU2488822045.USD","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623387210","title":"每周股票复盘：荣昌生物（688331）2025年净利润7.1亿元同比增148.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623387210","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623387210?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:24","pubTimestamp":1774718655,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，荣昌生物报收于123.58元，较上周的116.73元上涨5.87%。本周，荣昌生物3月26日盘中最高价报123.89元。业绩披露要点2025年公司主营收入32.51亿元，同比上升89.36%；归母净利润7.1亿元，同比上升148.33%；扣非净利润6767.55万元，同比上升104.49%。第四季度单季主营收入15.31亿元，同比上升201.43%；单季归母净利润12.6亿元，同比上升417.52%；单季扣非净利润6.13亿元，同比上升249.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622208158","title":"荣昌生物(09995)发布年度业绩，股东应占收益7.1亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2622208158","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622208158?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:08","pubTimestamp":1774620499,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物 发布截至2025年12月31日止年度业绩，该集团取得收益人民币32.42亿元，同比增加89.55%;母公司拥有人应占收益7.1亿元，去年同期则取得亏损14.68亿元;每股收益1.29元。2025年12月，该产品用于治疗gMG被纳入国家医保药品目录。截至2025年12月31日，泰它西普已获准入超过1200家医院。维迪西妥单抗已于2021年6月获中国药监局批准上市，并于同年7月开始销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09995","BK1161","LU1064130708.USD","LU1064131003.USD","LU2148510915.USD","LU2488822045.USD","688331","LU2328871848.SGD","BK1583","LU1969619763.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622942878","title":"荣昌生物：董事会审议通过《关于公司<2025年度总经理工作报告>的议案》等多项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2622942878","media":"证券日报网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622942878?lang=zh_cn&edition=full","pubTime":"2026-03-27 21:48","pubTimestamp":1774619280,"startTime":"0","endTime":"0","summary":"证券日报网讯 3月27日，荣昌生物发布公告称，公司第二届董事会第三十六次会议审议通过《关于公司<2025年度总经理工作报告>的议案》《关于公司<2025年度董事会工作报告>的议案》《关于公司<2025年年度报告全文及其摘要>的议案》等多项议案。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-27/doc-inhsmxrq1918117.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-27/doc-inhsmxrq1918117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1969619763.USD","688331","LU1064130708.USD","LU2488822045.USD","BK1574","BK0239","09995","LU2328871848.SGD","LU2148510915.USD","BK1161","BK1583","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621701053","title":"荣昌生物（688331）披露维迪西妥单抗新增适应症获批公告，3月23日股价下跌4.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621701053","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621701053?lang=zh_cn&edition=full","pubTime":"2026-03-23 22:06","pubTimestamp":1774274780,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，荣昌生物报收于111.31元，较前一交易日下跌4.64%，最新总市值为628.32亿元。该股当日开盘113.0元，最高117.0元，最低110.2元，成交额达8.6亿元，换手率为4.69%。近日，荣昌生物制药（烟台）股份有限公司收到国家药品监督管理局核准签发的《药品注册证书》，旗下自主研发的抗体偶联药物维迪西妥单抗新增适应症获批上市，用于治疗既往接受过至少一种系统治疗的不可切除或转移性HER2低表达且存在肝转移的成人乳腺癌患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300039589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","LU2328871848.SGD","LU1064131003.USD","09995","BK0239","BK1574","688331","BK1583","LU2148510915.USD","LU1969619763.USD","LU2488822045.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621764577","title":"荣昌生物(688331.SH)：维迪西妥单抗用于治疗HER2低表达且存在肝转移的乳腺癌适应症上市申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2621764577","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621764577?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:47","pubTimestamp":1774255668,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物 发布公告，近日，公司收到国家药品监督管理局核准签发的《药品注册证书》，维迪西妥单抗用于治疗HER2低表达且存在肝转移的乳腺癌的新适应症上市申请获得批准，这是维迪西妥单抗在国内获批的第四项适应症。截至本公告披露日，该药已相继获批用于治疗HER2过表达局部晚期或转移性胃癌、HER2过表达局部晚期或转移性尿路上皮癌、HER2阳性且存在肝转移的晚期乳腺癌和HER2低表达且存在肝转移的乳腺癌四个适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1969619763.USD","688331","BK1161","LU2328871848.SGD","LU1064130708.USD","LU2148510915.USD","LU2488822045.USD","LU1064131003.USD","09995","BK1583","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776015800009,"stockEarnings":[{"period":"1week","weight":-0.0913},{"period":"1month","weight":0.1394},{"period":"3month","weight":0.3973},{"period":"6month","weight":0.4667},{"period":"1year","weight":1.9023},{"period":"ytd","weight":0.7416}],"compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":-0.0356},{"period":"3month","weight":-0.0326},{"period":"6month","weight":0.0229},{"period":"1year","weight":0.2366},{"period":"ytd","weight":0.0044}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"荣昌生物制药(烟台)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17456人(较上一季度增加4.94%)","perCapita":"9343股","listingDate":"2022-03-31","address":"山东省烟台市福山区中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号","registeredCapital":"56447万元","survey":" 荣昌生物制药(烟台)股份有限公司的主营业务是研发、生产和销售医药产品、诊断试剂产品。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC148、RC278、RC288。","listedPrice":48},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,688331,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}